Biotech

Chinese scientists have bred mice from cells that might offer an alternative to human embryonic stem cells, producing the most definitive evidence yet that the technique could help sidestep many of the explosive ethical issues engulfing the controversial field but raising alarm that the advance...

Members of the Senate Small Business and Entrepreneurship Committee and the House Small Business, and Science and Technology Committees are meeting, yet again, to see if this time they can resolve the impasse of two very different SBIR reauthorization bills, (Senate S.1233 and House H.R.2965)....

A small Neenah biotechnology firm is venturing into food enhancement and anti-bacterial products based on its head's mainstay research into contemporary applications drawn from ancient medicinal remedies. Ayurvedic-Life International has made promising strides into therapies for insulin-deficient Type 2 diabetes sufferers, but still is far...

Biotechnology and medical device start-ups typically take many years and a lot of money to get to market. But Chrysalis Ventures, a venture capital firm in Louisville, Ky., takes a different approach to health care investments. Instead of backing the discovery of new drugs or the...

The Obama administration's lifting of Bush-era restrictions on federal funding of human embryonic stem cell research will result in a “massive step forward” in the long term, a Milwaukee-based researcher said today. But the rollout of the new guidelines has harmed research in the short...

The Medieval philosopher, Boethius, tackled the esoteric question of what is a human and came to the conclusion that “human is born of human”. There is a certain circular, facile truth in this conclusion that reminds one of the modern right-to-life refrain that “life begins...

At the annual BIO International Conference, this year held in Atlanta, the global accounting firm of Ernst & Young normally rolls out its annual report on the biotech industry in a special session. This report, known as “Beyond Borders: Ernst & Young Global Biotechnology Report...

The House just passed a controversial SBIR reauthorization bill with the usual shenanigans by Rep. Nydia Velazquez (D-NY). As in last year's reauthorization debacle, Ms Velazquez completely stifled any testimony contrary to her preferences. The major point of contention is whether to allow companies that...